If Lilly receives Priority Review designation (possible given the unmet medical need in obesity), the review timeline could compress by several months
Narration: And now I haven't had the medicine at all since October and about 60 pounds loss overall
These effects become therapeutically interesting in obesity because they suggest that glucagon receptor activation could complement appetite suppression by increasing caloric expenditure and improving hepatic lipid handling
Falk Pharma, Eisai, Enyo, Galapagos, Galmed, Genetech, Genfit, Genflow Biosciences, Gilead Sciences, Intercept, Inventiva, Janssens Pharmaceutica, PRO.MED.CS Praha, Julius Clinical, Madrigal, Medimmune, Merck Sharp & Dome, Mursla Bio, NGM Bio, Novartis, Novo Nordisk, Promethera, Roche, Siemens Healthineers, and lectured for for Abbvie, Allergan, Bayer, Eisai, Genfit, Gilead Sciences, Janssens Cilag, Intercept, Inventiva, Merck Sharp & Dome, Novo Nordisk, Promethera, Siemens